John Haurum

Chairman of the Board of Directors and Non-executive Director at CatalYm, Adcendo, Agomab, Neophore, Solid Therapeutics, Storm and SynKlino

Speaker

John Haurum is chair of the board of Adcendo (DK), Solid Therapeutics (DK), and Synklino (DK) and holds non-executive director positions in MC2 Therapeutics (DK), Neophore (UK), and Saniona (DK).

He was previously the CEO of F-star in Cambridge, UK (2012-2018), where he built a successful biotech company, that progressed several products into clinical development, and completed four M&A or license transactions with biopharma partners (BMS, AbbVie, Merck, and Denali).

Previously he was VP Research at ImClone Systems, New York (2010-2012) and cofounder and Chief Scientific Officer of Symphogen A/S, Denmark (2000-2009). After graduating in Medicine in Aarhus Denmark 1992, Dr. Haurum received a D.Phil. in Immunology from the Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, England.